Risk of uterine, ovarian and breast cancer following pelvic inflammatory disease: a nationwide population-based retrospective cohort study

BMC Cancer

Research Article

Yung-Yen Chiang¹  Jeng-Hsiu Hung²  Cheng-Che Shen³  Li-Yu Hu⁴  Albert C. Yang⁵  Shih-Jen Tsai⁵ 

[1] Department of Dental Technology and Materials, Central Taiwan University of Science and Technology, Taichung, Taiwan;Department of Obstetrics and Gynecology, Taipei Tzu Chi Hospital, Taipei, Taiwan;School of Medicine, Tzu Chi University, Hualien, Taiwan;School of Medicine, National Yang-Ming University, Taipei, Taiwan;Department of Psychiatry, Chiayi Branch, Taichung Veterans General Hospital, Chiayi, Taiwan;Department of Information Management, National Chung-Cheng University, Chiayi, Taiwan;School of Medicine, National Yang-Ming University, Taipei, Taiwan;Department of Psychiatry, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan;School of Medicine, National Yang-Ming University, Taipei, Taiwan;Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan;

关键词: Pelvic inflammatory disease;    Uterine cancer;    Ovarian cancer;    Breast cancer;    Retrospective cohort study;   

DOI  :  10.1186/s12885-016-2857-1

 received in 2015-12-15, accepted in 2016-10-19,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundPelvic inflammatory disease (PID) is characterized by infection and inflammation of the upper genital tract in women and is associated with health sequelae. We used a nationwide population-based retrospective cohort study to explore the relationship between PID and the subsequent development of gynecological cancers including ovarian, breast or uterine cancer.MethodsWe identified subjects diagnosed with PID between January 1st, 2000 and December 31st, 2002 in the Taiwan National Health Insurance Research Database. A comparison cohort constructed for patients without PID were matched according to age and sex. All PID patients and control groups were observed until diagnosed with ovarian, breast or uterine cancer, or until death, withdrawal from the NHI system, or until December 31st, 2009.ResultsThe PID cohort consisted of 32,268 patients, and an equal number of matched controls without PID. The adjusted hazard ratio (HR) of ovarian, breast or uterine cancer in subjects with PID were: HR 1.326 (95 % confidence interval: 0.775–2.269), HR: 1.039 (95 % confidence interval: 0.862–1.252), and HR: 1.439 (95 % confidence interval: 0.853–2.426) respectively in comparison with controls during follow-up.ConclusionsThis large nationwide population-based cohort study suggests that there is no increased risk for ovarian, breast or uterine cancer among women who have PID compared to a matching population.

【 授权许可】

CC BY   
© The Author(s). 2016